For the quarter ending 2026-03-31, IMCR had -$8,900K decrease in cash & cash equivalents over the period. -$15,556K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 106,677 | 104,478 | 103,693 | - |
| Cost of revenue from sale of therapies | 434 | 2,703 | 4,255 | - |
| PRAMEPrograms | 21,214 | 22,644 | 97,933 | - |
| Tebentafusp Programs | 8,239 | 10,628 | 48,603 | - |
| Infectious Disease Programs | 846 | 2,373 | 6,807 | - |
| Other Clinical And Pre Clinical Costs | 8,493 | 17,681 | 68,519 | - |
| R&d expenses-External RD | 38,792 | 53,326 | 221,862 | - |
| R&d expenses-Salaries And Other Employee Related Cost | 14,140 | 14,016 | 59,832 | - |
| Sg&a expenses-Salaries And Other Employee Related Cost | 13,090 | 9,574 | 64,128 | - |
| Sg&a expenses-Other Selling General And Administrative Expenses | 21,065 | 26,844 | 103,913 | - |
| Other segment (expense) income, net | 6,185 | 28,075 | 44,124 | - |
| Net income | 12,971 | -30,060 | -177 | -5,277 |
| Share-based compensation expense | 6,302 | 8,339 | 9,837 | 19,522 |
| Depreciation | 948 | 834 | 798 | 1,634 |
| Unrealized foreign exchange gains, net | 3,490 | -3,844 | 9,622 | 607 |
| Unrealized gains on marketable securities | 1,776 | 4,504 | 5,062 | 10,162 |
| Loss on loan extinguishment | - | 0 | - | - |
| Non-cash lease expense | 627 | 667 | 567 | 1,114 |
| Deferred income taxes | - | 14,790 | - | - |
| Other | -534 | -537 | -527 | -1,049 |
| (increase) decrease in accounts receivable | 7,930 | -1,994 | 5,989 | 3,341 |
| Increase in prepayments and other current assets | 18,772 | 1,016 | 6,089 | -365 |
| Increase in accounts payable | 5,974 | 1,418 | -287 | -3,587 |
| Decrease in accrued expenses | -8,303 | -22,031 | 15,133 | 22,787 |
| Decrease in deferred revenue | -146 | -144 | -146 | -97 |
| Decrease in other operating liabilities | - | 0 | 0 | 0 |
| (decrease) increase in operating lease liabilities | -864 | -2,617 | 1,052 | -528 |
| Decrease (increase) in other operating assets | -150 | 4,706 | 4,998 | -3,527 |
| Net cash (used in) provided by operating activities | -13,775 | -32,655 | -4,456 | 26,399 |
| Purchase of marketable securities | - | 0 | 0 | 30,000 |
| Proceeds from sale of property, plant and equipment | - | 0 | - | - |
| Proceeds from sale of marketable securities | 6,000 | 2,000 | 6,000 | 10,000 |
| Purchase of property and equipment | 1,781 | 2,880 | 748 | 712 |
| Net cash provided by investing activities | 4,219 | -880 | 5,252 | -20,712 |
| Proceeds from issue of ordinary shares, net | - | 0 | - | - |
| Proceeds from exercise of share options | 656 | 4,284 | 1,866 | 6,221 |
| Loan repayments | - | 0 | - | - |
| Debt prepayments and extinguishments | - | 0 | - | - |
| Proceeds from issue of convertible senior notes | - | - | 0 | 0 |
| Non-current interest-bearing loan received | - | 0 | - | - |
| Debt issuance payments | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 656 | 4,284 | 1,866 | 6,221 |
| (decrease) increase in cash and cash equivalents | -8,900 | -29,251 | 2,662 | 11,908 |
| Net foreign exchange difference on cash held | -6,134 | -1,453 | 28,112 | - |
| Cash and cash equivalents at beginning of period | 467,709 | 498,413 | 455,731 | - |
| Cash and cash equivalents at end of period | 452,675 | 467,709 | 498,413 | - |
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)